Over the past few years, there has been an increase in the number of pharmaceutical companies developing FSHD therapeutics. These strategies primarily focus on blocking DUX4, the toxic element that causes FSHD. These treatments are considered “disease modifying” because…
Dry eyes, also known as Ocular Surface Disease (OSD), is a common issue with many in the FSHD community. Symptoms are often described as grittiness, itchiness, or burning especially upon waking up in the morning and/or later in the…
Everything we do propels us faster toward treatments and a cure We often speak of “filling potholes” and “overcoming obstacles” toward treatments and cures, but what the FSHD Society has done is much more dynamic. We are not just…
When we say that we are embarking on a new era in clinical trials, what do we mean? After all, we have seen previous FSHD trials, including those by Wyeth, aTyr, Acceleron, and Fulcrum’s ReDUX4. What makes the current…